MEDP 📈 Medpace Holdings - Overview
Exchange: NASDAQ • Opening Hours • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58506Q1094
MEDP: Clinical Trials, Drug Development, Medical Device Development, Laboratory Services
Medpace Holdings, Inc. is a leading provider of clinical research-based drug and medical device development services, operating across North America, Europe, and Asia. The company's comprehensive suite of services supports the entire clinical development process, from Phase I to Phase IV, across various therapeutic areas.
Medpace offers a range of services tailored to the needs of the pharmaceutical, biotechnology, and medical device industries. These services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, new drug application submissions, and post-marketing clinical support. This enables clients to navigate the complex clinical development process efficiently and effectively.
In addition to its core services, Medpace provides specialized support for clinical trials, including bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support. This comprehensive approach enables clients to access a single, trusted partner for all their clinical development needs.
Founded in 1992, Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio, and has established itself as a trusted partner for companies seeking to bring innovative treatments and devices to market. With a strong track record of delivering high-quality services, Medpace is well-positioned to support the evolving needs of the life sciences industry.
Additional Sources for MEDP Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MEDP Stock Overview
Market Cap in USD | 9,932m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC SubIndustry | Life Sciences Tools & Services |
TER | 0.00% |
IPO / Inception | 2016-08-11 |
MEDP Stock Ratings
Growth 5y | 85.0 |
Fundamental | 66.2 |
Dividend | - |
Rel. Performance vs Sector | 0.37 |
Analysts | 3.64/5 |
Fair Price Momentum | 339.39 USD |
Fair Price DCF | 382.54 USD |
MEDP Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.00% |
MEDP Growth Ratios
Growth Correlation 3m | -45% |
Growth Correlation 12m | 17.5% |
Growth Correlation 5y | 91.3% |
CAGR 5y | 33.69% |
CAGR/Mean DD 5y | 2.77 |
Sharpe Ratio 12m | 0.50 |
Alpha vs SP500 12m | -24.38 |
Beta vs SP500 5y weekly | 1.39 |
Volatility GJR Garch 1y | 36.17% |
Current Volume | 382k |
Average Volume 20d | 389.9k |
As of November 21, 2024, the stock is trading at USD 326.09 with a total of 381,966 shares traded.
Over the past week, the price has changed by -9.90%, over one month by -7.60%, over three months by -16.25% and over the past year by +18.16%.
Yes, based on ValueRay Fundamental Analyses, Medpace Holdings (NASDAQ:MEDP) is currently (November 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 66.23 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MEDP as of November 2024 is 339.39. This means that MEDP is currently overvalued and has a potential downside of 4.08%.
- Strong Buy: 4
- Buy: 0
- Hold: 6
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, MEDP Medpace Holdings will be worth about 381.9 in November 2025. The stock is currently trading at 326.09. This means that the stock has a potential upside of +17.12%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 355.3 | 8.9% |
Analysts Target Price | 269.5 | -17.4% |
ValueRay Target Price | 381.9 | 17.1% |